Physician profile
Abraham Cherian
NPI 1841491982
$1,093.19
in general payments reported to CMS, 2019-2025
15 companies · $149 in 2025
The $149 reported for 2025 was more than what a typical Anesthesiology provider received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.40 · 2020: $24.54 · 2021: $119 · 2022: $295 · 2023: $116 · 2024: $322 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $587.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $353.04 | 2019-2025 | Xifaxan, Plenvu, Relistor |
| Pacira Pharmaceuticals Incorporated | $145.92 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $139.03 | 2021-2024 | Entyvio |
| Merck Sharp & Dohme LLC | $90.82 | 2021-2024 | Dificid, Bridion |
| Lilly USA, LLC | $64.89 | 2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $61.00 | 2024 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $56.19 | 2024-2025 | Dupixent |
| Ardelyx, INC. | $36.98 | 2024 | Ibsrela |
| Ambu INC. | $36.04 | 2024-2025 | |
| Nestle Healthcare Nutrition INC. | $32.23 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $17.56 | 2024 | |
| Qol Medical, LLC | $16.55 | 2023 | Sucraid |
| Janssen Biotech, INC. | $16.48 | 2024 | Tremfya |
| Intercept Pharmaceuticals, INC. | $13.90 | 2025 | |
| Ferring Pharmaceuticals INC. | $12.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abraham Cherian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.